Vaccine effectiveness in pandemic influenza – primary care reporting (VIPER): an observational study to assess the effectiveness of the pandemic influenza A (H1N1)v vaccine

CR Simpson,¹* LD Ritchie,² C Robertson,³⁴ A Sheikh¹ and J McMenamin⁴

¹Allergy & Respiratory Research Group, Centre for Population Health Sciences, University of Edinburgh, UK
²Centre of Academic Primary Care, University of Aberdeen, UK
³Department of Statistics and Modelling Science, University of Strathclyde, Glasgow, UK
⁴Health Protection Scotland, Glasgow, UK

*Corresponding author

Executive summary

Health Technology Assessment 2010; Vol. 14: No. 34, 313–346
DOI: 10.3310/hta14340-05
Executive summary

Objectives

To determine influenza A (H1N1)v vaccine effectiveness (VE) in the Scottish population at an early stage of the 2009–10 H1N1v vaccination programme, using a sentinel surveillance network of 41 general practices contributing to the Practice Team Information (PTI) network.

Methods

The PTI network of general practices covers a 5% sample of the Scottish population (n = 246,368). Using the unique Community Health Index (CHI) number, general practice patient-level data were extracted and linked to the Scottish Morbidity Record (SMR) catalogue, which has information on all inpatient hospitalisations in Scotland. We also used the Health Protection Scotland (HPS) data set, which consists of laboratory-confirmed cases of influenza A (H1N1)v from the practices. The study involved a longitudinal evaluation of the aspect of the influenza A (H1N1)v vaccination programme implemented through general practice in autumn/winter 2009. Primary care practices were given financial incentives to record and code additional data electronically, over and above that routinely recorded for clinical care or as part of the PTI project, including: H1N1 vaccination status, age, deprivation status, pregnancy, and, where it was feasible, health worker status. During the study period, we assessed the vaccination uptake in the relevant high-risk populations, i.e. pregnant women, children (< 5 years), health-care workers and patients with at-risk comorbidities. For VE using information from linked virological swab data, a logistic regression model was fitted adjusting for the effects of gender, age, deprivation status, pregnancy, and, where it was feasible, health worker status. During the study period, we assessed the vaccination uptake in the relevant high-risk populations, i.e. pregnant women, children (< 5 years), health-care workers and patients with at-risk comorbidities. For VE using information from linked virological swab data, a logistic regression model was fitted adjusting for the effects of gender, age, deprivation status, pregnancy, and, where it was feasible, health worker status. During the study period, we assessed the vaccination uptake in the relevant high-risk populations, i.e. pregnant women, children (< 5 years), health-care workers and patients with at-risk comorbidities. For VE using information from linked virological swab data, a logistic regression model was fitted adjusting for the effects of gender, age, deprivation status, pregnancy, and, where it was feasible, health worker status. During the study period, we assessed the vaccination uptake in the relevant high-risk populations, i.e. pregnant women, children (< 5 years), health-care workers and patients with at-risk comorbidities. For VE using information from linked virological swab data, a logistic regression model was fitted adjusting for the effects of gender, age, deprivation status, pregnancy, and, where it was feasible, health worker status. During the study period, we assessed the vaccination uptake in the relevant high-risk populations, i.e. pregnant women, children (< 5 years), health-care workers and patients with at-risk comorbidities. For VE using information from linked virological swab data, a logistic regression model was fitted adjusting for the effects of gender, age, deprivation status, pregnancy, and, where it was feasible, health worker status. During the study period, we assessed the vaccination uptake in the relevant high-risk populations, i.e. pregnant women, children (< 5 years), health-care workers and patients with at-risk comorbidities. For VE using information from linked virological swab data, a logistic regression model was fitted adjusting for the effects of gender, age, deprivation status, pregnancy, and, where it was feasible, health worker status. During the study period, we assessed the vaccination uptake in the relevant high-risk populations, i.e. pregnant women, children (< 5 years), health-care workers and patients with at-risk comorbidities. For VE using information from linked virological swab data, a logistic regression model was fitted adjusting for the effects of gender, age, deprivation status, pregnancy, and, where it was feasible, health worker status.

Results

At 25 December 2009, vaccine uptake estimates for the study population were 12.0% [95% confidence interval (CI) 11.9 to 12.1]. For those patients in an at-risk group (n = 59,721), the uptake rate was 37.5% (95% CI 37.1 to 37.9). Amongst 2203 pregnant women (4.3% of women aged 15–44 years) and 1314 health-care workers (0.8% of working-aged people aged 18–65 years), rates of vaccine uptake were 33.0% (95% CI 31.0 to 34.9) and 26.4% (95% CI 24.0 to 28.8), respectively. More male [odds ratio (OR) 2.67, 95% CI 1.44 to 4.96] health-care workers were vaccinated than female health-care workers. Among the 1492 patients swabbed, 467 were positive for H1N1, giving a positivity rate of 31.3% (95% CI 29.0 to 33.7). Among those in a clinical risk group who were not vaccinated, 41.3% (95% CI 35.6 to 46.9) tested positive for influenza A (H1N1) v. This represented a significant difference from the H1N1 positivity percentage among patients with no clinical risk (p < 0.01). Among those vaccinated and in a clinical risk group, only one patient (5%, 95% CI 0.3 to 23.6) tested after vaccination was positive for influenza A (H1N1) v. By comparing postvaccination swabs in those who were vaccinated with swabs taken in those who remained unvaccinated, the VE was found to be 95.0% (95% CI 76.0 to 100.0). There were 2739 admissions to hospital in the study population, of which 1241 were emergency admissions. All 48 emergency hospitalisations for influenza and pneumonia occurred in patients who did not receive the vaccine. VE for single or combined end points of influenza and pneumonia hospitalisation for all patients was estimated at 100.0% (95% CI 100.0 to 100.0). There were 132 hospitalisations in the unvaccinated group versus five in the vaccinated group for cardiovascular-related conditions. There were 193 hospitalisations in the unvaccinated group versus nine in those vaccinated in the group of patients admitted for influenza, pneumonia,
chronic obstructive pulmonary disease (COPD) and cardiovascular-related conditions. VE for cardiovascular-related conditions alone, or in individuals with influenza, pneumonia COPD and cardiovascular-related conditions, was 71.1% (95% CI 11.3 to 90.6) and 64.7% (95% CI 12.0 to 85.8), respectively.

**Implications for practice**

Policy-makers and clinicians should be encouraged that the VE estimates obtained are comparable to those found for seasonal influenza and should strengthen the evidence base for health-care practitioners involved in distributing vaccine in other countries. Influenza A (H1N1)v immunisation in primary health care settings is both effective and widely acceptable, as evidenced by high uptake rates, and should continue to be the mainstay of disease prevention for at-risk patients.

**Research recommendations**

A further analysis encompassing the whole influenza season is required to encompass more days of vaccination exposure, which will increase precision (with resulting narrower confidence intervals). For pregnant women and under-5-year-olds, a further study using a greater time period of exposure is required to calculate and present meaningful results. A future study that will repeat this data linkage and allow the calculation of longer-term VE (in reducing both morbidity and mortality) should be undertaken later in 2010.

**Conclusions**

Evidence from swabs submitted from patients in the cohort presenting with influenza-like illness in general practice suggests that the introduction of influenza A (H1N1)v vaccine in Scotland during 2009 was associated with a high degree of protection against influenza A (H1N1)v. In addition, receipt of influenza A (H1N1)v vaccine was associated with a reduction in both admission for cardiac-related conditions and for the combined category of influenza, pneumonia, COPD and cardiac conditions. Policy-makers ought to be encouraged that the VE estimates obtained are comparable to those found for seasonal influenza. Additionally, as the first large-scale demonstration of effectiveness in a UK population, these interim results should help strengthen the evidence base for health-care practitioners involved in distributing influenza A (H1N1)v vaccine in other countries, now that the phased roll-out has been completed in the UK. Influenza A (H1N1)v immunisation in the primary health care setting is both effective and widely acceptable, as evidenced by high uptake rates, and should continue to be a mainstay of disease prevention for at-risk patients. Whether the reduced incidence of severe complications of influenza will persist or a reduction in mortality has occurred will only be apparent when data collected from later in 2010 are analysed.

**Publication**

How to obtain copies of this and other HTA programme reports
An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).

Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue.

How to order:
– fax (with credit card details)
– post (with credit card details or cheque)
– phone during office hours (credit card only).

Additionally the HTA website allows you to either print out your order or download a blank order form.

Contact details are as follows:
Synergie UK (HTA Department)  Email: orders@hta.ac.uk
Digital House, The Loddon Centre
Wade Road
Basingstoke
Hants RG24 8QW
Tel: 0845 812 4000 – ask for ‘HTA Payment Services’
(out-of-hours answer-phone service)
Fax: 0845 812 4001 – put ‘HTA Order’ on the fax header

Payment methods
Paying by cheque
If you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.

Paying by credit card
You can order using your credit card by phone, fax or post.

Subscriptions
NHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40–50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.

How do I get a copy of HTA on DVD?
Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.

The website also provides information about the HTA programme and lists the membership of the various committees.
The National Institute for Health Research

The National Institute for Health Research (NIHR) has been established as a part of the Government’s strategy, ‘Best Research for Best Health’. It provides the framework through which the research staff and research infrastructure of the NHS in England is positioned, maintained and managed as a national research facility.

The NIHR provides the NHS with the support it needs to conduct first-class research funded by the Government and its partners alongside high-quality patient care, education and training. Its aim is to support outstanding individuals (both leaders and collaborators), working in world-class facilities (both NHS and university), conducting leading-edge research focused on the needs of patients.

This themed issue of the *Health Technology Assessment* journal series contains a collection of research commissioned by the NIHR as part of the Department of Health’s (DH) response to the H1N1 swine flu pandemic. The NIHR through the NIHR Evaluation Trials and Studies Coordinating Centre (NETSCC) commissioned a number of research projects looking into the treatment and management of H1N1 influenza.

NETSCC managed the pandemic flu research over a very short timescale in two ways. Firstly, it responded to urgent national research priority areas identified by the Scientific Advisory Group in Emergencies (SAGE). Secondly, a call for research proposals to inform policy and patient care in the current influenza pandemic was issued in June 2009. All research proposals went through a process of academic peer review by clinicians and methodologists as well as being reviewed by a specially convened NIHR Flu Commissioning Board.

The final reports from these projects have been peer reviewed by a number of independent expert referees before publication in this journal series.

---

**Criteria for inclusion in the HTA journal series**

Reports are published in the HTA journal series if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

Reviews in *Health Technology Assessment* are termed ‘systematic’ when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

The research reports in this themed issue were funded through the Cochrane Collaboration; the Health Services Research programme (HSR); the Health Technology Assessment programme (HTA); the Policy Research Programme (PRP); the Public Health Research programme (PHR); and the Service Delivery and Organisation Programme (SDO).

The Cochrane Collaboration is an international not-for-profit and independent organisation, dedicated to making up-to-date, accurate information about the effects of health care readily available worldwide. It produces and disseminates systematic reviews of health-care interventions and promotes the search for evidence in the form of clinical trials and other studies of interventions. Cochrane reviews and the Cochrane Central Register of Controlled Trials are published and updated in *The Cochrane Library* (www.cochranelibrary.com).

The HSR programme aims to lead to an increase in service quality and patient safety through better ways of planning and providing health services. It funds both primary research and evidence syntheses, depending on the availability of existing research and the most appropriate way of responding to important knowledge gaps.
The HTA programme produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The PRP provides the evidence base for policy development on public health and social care issues. It funds research in three main ways: 5-year programmes of research in 16 research units, a primary-care research centre, a public health research consortium, and a surveillance unit; programmes of interlinked studies on key policy initiatives; and single projects and literature reviews.

The PHR programme evaluates public health interventions, providing new knowledge on the benefits, costs, acceptability and wider impacts of non-NHS interventions intended to improve the health of the public and reduce inequalities in health. The scope of the programme is multi-disciplinary and broad, covering a range of interventions that improve public health.

The SDO programme commissions research evidence that improves practice in relation to the organisation and delivery of health care. It also builds research capability and capacity amongst those who manage, organise and deliver services – improving their understanding of the research literature and how to use research evidence.

The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the referees for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report. The views expressed in this publication are those of the authors and not necessarily those of the NIHR or the Department of Health.

Editor-in-Chief: Professor Tom Walley CBE
Series Editors: Dr Martin Ashton-Key, Dr Aileen Clarke, Professor Chris Hyde, Dr Tom Marshall, Dr John Powell, Dr Rob Riemsma and Professor Ken Stein
Editorial Contact edit@southampton.ac.uk